On January 17, 2022 Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, reported that patents no CN108495934 and JP6974350 have been granted by the Chinese and Japanese Patent Offices, respectively (Press release, Targovax, JAN 17, 2022, View Source [SID1234605505]). The patents cover the use of ONCOS-102 in combination with chemotherapy in malignant mesothelioma.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Andreas Berg Storsve, VP Business Development and IP at Targovax, said: "We are delighted that these patents have been granted, further strengthening Targovax’s intellectual property portfolio. The 30-month data from our ONCOS-102 trial in mesothelioma demonstrate very strong survival outcomes in the first-line setting, and this remains an area of high medical need. Securing these patents protects our innovative oncolytic immunotherapy platform and strengthens our future market position in the major Asian markets."
Targovax’s lead product candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to selectively infect cancer cells and activate the immune system. In December 2021, the 30-month follow-up in the malignant pleural mesothelioma (MPM) trial showed 25.0 months median overall survival (mOS) for patients in first-line treatment with ONCOS-102 plus chemotherapy, which is very encouraging in this patient population with poor prognosis.
The US FDA granted ONCOS-102 Fast Track designation for MPM in February 2021 based on the encouraging pre-clinical and clinical data package. ONCOS-102 also has orphan drug designation for MPM with both the US FDA and the European Medicines Agency.